Biotech

Epstein Fallout: Joi Ito Resigns From MIT Media Lab, Multiple Boards

8 days ago   |   By Xconomy

The ripple effects from a report Friday in The New Yorker about ties between the MIT Media Lab and disgraced financier and convicted sex offender Jeffrey Epstein continue to spread. After Joi Ito resigned as the Media Lab's director on Saturday, he also relinquished high-profile board seats with The New York Times Company , the Knight Foundation , the MacArthur Foundation , and PureTech Health , a Boston-based biotech company. Ito also resigned a visiting professorship at Harvard Law School, according to a spokeswoman. These are nowhere near all the boards that Ito is listed as sitting on...
Read more ...

 

Ito out at PureTech, MIT after Epstein funding scandal exposed

Ito out at PureTech, MIT after Epstein funding scandal exposed

8 days ago   |   By Fierce Biotech

Joichi Ito has been forced out as head of the Media Lab at MIT as well as from biotech builder PureTech's board after financial ties to the deceased sex offender Jeffrey Epstein were uncovered.
Read more ...

 


Search by Tags

   Biotech      BioTech      Health      Boston      Boston blog main      Boston top stories      National blog main      National top stories      New York blog main      Bill gates      Connected camps      Digital Garage      Fundraising      Harvard law school      Japan society      Jeffrey Epstein      Joi Ito      Knight Foundation      Lawrence Lessig      Leon Black      Macarthur foundation      Media Lab      MIT      New York Times Company      New Yorker      Pure health      Resignations      Ronan farrow      Seth lloyd      The Engine      Xperience  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Why Menlo Ventures Backed Its First Construction Tech Firm

Why Menlo Ventures Backed Its First Construction Tech Firm

Fieldwire , whose mobile app helps builders and construction crews coordinate their work, announced today it has lined up a total of $33.5 million across two newly disclosed... Read more ...

HMS's $36M Deal to Buy VitreosHealth Combines Complementary Firms

HMS's $36M Deal to Buy VitreosHealth Combines Complementary Firms

One Texas-based healthcare software business has acquired another in an all-cash deal worth $36.5 million, the companies announced late Monday. Irving, TX-based HMS Holdings... Read more ...

ESnet a Key Partner on Project to Build Novel Network Research Infrastructure

ESnet a Key Partner on Project to Build Novel Network Research Infrastructure

Anticipated FABRIC topology at the end of construction. The National Science Foundation is funding a collaborative effort to create a nationwide research infrastructure that... Read more ...

Automated Trucking Company TuSimple Adds $120M More From Investors

Automated Trucking Company TuSimple Adds $120M More From Investors

UPS, the global package delivery giant, took a minority stake this summer in TuSimple, a self-driving trucking company, but didn't reveal financial details. On Tuesday, the San... Read more ...

Amplyx Inks Novartis Deal for Another Compromised-Immune System Drug

Amplyx Inks Novartis Deal for Another Compromised-Immune System Drug

Amplyx Pharmaceuticals, which is testing a new type of drug against life-threatening infections acquired by patients with compromised immune systems, has acquired the rights to... Read more ...

Lundbeck Paying Nearly $2B for Alder to Follow Migraine Rivals to Market

Lundbeck Paying Nearly $2B for Alder to Follow Migraine Rivals to Market

Denmark's neuroscience-focused pharma firm Lundbeck has agreed to pay $1.95 billion to acquire Seattle-based Alder BioPharmaceuticals to boost its late-stage pipeline and... Read more ...

KATRIN Cuts the Mass Estimate for the Elusive Neutrino in Half

KATRIN Cuts the Mass Estimate for the Elusive Neutrino in Half

A diagram of the layout and major features of the KATRIN experimental facility at the Karlsruhe Institute of Technology. (Credit: Karlsruhe Institute of Technology) Note: This... Read more ...

INmune Bio Invited to Speak on Company's Advancements in Cancer Treatments...

La Jolla, CA., Sept. 17, 2019 - INmune Bio, Inc. , an immunology company focused on developing treatments that harness the patient's innate immune system to fight disease... Read more ...

Equillium to Host Business Update Call on October 1, 2019

LA JOLLA, Calif., Sept. 17, 2019 - Equillium, Inc. , a clinical-stage biotechnology company, leveraging deep understanding of immunobiology to develop products to treat severe... Read more ...

AXIM® Biotechnologies Announces Cultivation Agreement to Establish Company's...

SAN DIEGO, Sept. 17, 2019 - AXIM® Biotechnologies, Inc. (“AXIM® Biotech,” “AXIM” or “the Company”) , a world leader in cannabinoid research and development, today announced... Read more ...